wr 1065 has been researched along with Cystic Fibrosis of Pancreas in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cerami, A; Peterson, CM; Tabachnik, NF | 1 |
| Blackburn, P; Cerami, A; Peterson, CM; Tabachnik, NF | 1 |
2 other study(ies) available for wr 1065 and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Studies on the reduction of sputum viscosity in cystic fibrosis using an orally absorbed protected thiol.
Topics: Adolescent; Adult; Amifostine; Animals; Child; Cystic Fibrosis; Diamines; Expectorants; Humans; In Vitro Techniques; Lung; Male; Mercaptoethylamines; Mice; Mice, Inbred BALB C; Organothiophosphorus Compounds; Rabbits; Sputum; Sulfhydryl Compounds; Viscosity | 1980 |
Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721.
Topics: Administration, Oral; Amifostine; Animals; Biotransformation; Blood Proteins; Cystic Fibrosis; Diamines; Female; Humans; Mercaptoethylamines; Mucins; Organothiophosphorus Compounds; Protein Binding; Rabbits; Sputum; Sulfhydryl Compounds | 1982 |